Multiple myeloma survival has significantly improved in recent years, due to novel agents that are available for treatment. The anti-CD38 monoclonal antibody Daratumumab is particularly efficient for patients with relapse/refractory disease, and many studies have shown its unprecedented efficacy also as a first treatment. However, to avoid the incidence of infusion reactions, long infusion schedules of 8 h at first dose and 4 h in the following doses are required, which can reduce the compliance of patients and health care professionals. A reduced infusion time of 90 min has been reported previously, but data are missing on the prolonged safety of this over time as well as the efficacy of this approach. In this work, we investigate the safety of 484 rapid Daratumumab infusions given early after the second dose over a 22 months period in 39 myeloma patients.

Gozzetti, A., Bacchiarri, F., Sammartano, V., Defina, M., Sicuranza, A., Mecacci, B., et al. (2020). Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients. FRONTIERS IN ONCOLOGY, 10, 1-6 [10.3389/fonc.2020.570187].

Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients

Gozzetti, Alessandro;Bacchiarri, Francesca;Sammartano, Vincenzo;Defina, Marzia;Sicuranza, Anna;Mecacci, Bianca;Cencini, Emanuele;Raspadori, Donatella;Bocchia, Monica
2020-01-01

Abstract

Multiple myeloma survival has significantly improved in recent years, due to novel agents that are available for treatment. The anti-CD38 monoclonal antibody Daratumumab is particularly efficient for patients with relapse/refractory disease, and many studies have shown its unprecedented efficacy also as a first treatment. However, to avoid the incidence of infusion reactions, long infusion schedules of 8 h at first dose and 4 h in the following doses are required, which can reduce the compliance of patients and health care professionals. A reduced infusion time of 90 min has been reported previously, but data are missing on the prolonged safety of this over time as well as the efficacy of this approach. In this work, we investigate the safety of 484 rapid Daratumumab infusions given early after the second dose over a 22 months period in 39 myeloma patients.
Gozzetti, A., Bacchiarri, F., Sammartano, V., Defina, M., Sicuranza, A., Mecacci, B., et al. (2020). Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients. FRONTIERS IN ONCOLOGY, 10, 1-6 [10.3389/fonc.2020.570187].
File in questo prodotto:
File Dimensione Formato  
fonc-10-570187-2.pdf

accesso aperto

Tipologia: PDF editoriale
Licenza: Creative commons
Dimensione 336.73 kB
Formato Adobe PDF
336.73 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1122571